Enfermedad hemolítica del feto y del recién nacido por aloanticuerpos contra el antígeno M

Páez, Marco; Jiménez, M.P.; Corredor, Ana

doi:10.7705/biomedica.5930

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within cases of ABO blood group incompatibility between mothers and infants, approximately one-fifth of cases develop ABO hemolytic disease (17). The majority of affected children exhibit no additional abnormalities beyond jaundice.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease

Liu,

Dong,

Qin

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

ObjectiveThe purpose of this study is to examine the prognostic significance of the amalgamated indicators, reticulocyte percentage (RET%), lactate dehydrogenase (LDH), and γ-Glutamyltransferase (γ-GT), in neonatal ABO hemolytic disease.MethodsA total of 137 hospitalized children with pathological jaundice were included. Based on their medical conditions, they were categorized into two groups, hemolytic (67 cases) and non-hemolytic (70 cases). Pearson linear correlation and binary logistic multivariate analysis were used to analyze LDH, γ-GT, RET% and hemolysis. Furthermore, the predictive value of the combined predictors of RET%, LDH, and γ-GT on ABO neonatal hemolytic disease was evaluated using the ROC curve analysis.ResultsThe laboratory indexes of the two groups were subject to analysis using binary logistic regression to identify suspicious influencing factors. The study revealed that RET%, LDH, and γ-GT were independent risk factors for hemolysis. Pearson linear correlation analysis indicated a positive correlation between LDH and γ-GT with RET% (r = 0.529, P < 0.01; r = 0.526, P = <0.01, respectively). Furthermore, the predictive value of each combined predictor was obtained using the ROC curve, and it was observed that combined predictor L (RET% + LDH + γ-GT)>L1 (RET% + LDH)>L2 (RET% + γ-GT).ConclusionCombined predictor L (RET% + LDH + γ-GT)demonstrate its optimal diagnostic efficacy, offering a novel approach towards diagnosing early-onset ABO hemolytic disease of the newborn.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease

Liu,

Dong,

Qin

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…La enfermedad hemolítica del recién nacido causada por incompatibilidad ABO representa solo un tercio de los casos de este tipo, en el Ecuador no existen datos claros de prevalencia de esta patología, además que suelen restarle interés por la leve o moderada afectación prenatal y postnatal, siendo mayor por causa de incompatibilidad Rh (29,30). Una de las complicaciones que puede conllevar la enfermedad hemolítica del recién nacido es la hiperbilirrubinemia grave, misma que aumenta la tasa de morbilidad en esta población, implicando riesgos en algunas ocasiones incluso en cuanto al tratamiento (7,31,32).…”

Section: Complicaciones Por Incompatibilidad Abounclassified

Incompatibilidad ABO. Una revisión bibliográfica

Guerra¹,

Carguaytongo²,

Cueva³

et al. 2022

View full text Add to dashboard Cite

Introducción: la sangre es un fluido corporal con una función importantísima dentro de varios procesos biológicos y metabólicos. Los antígenos de tipo A y B determinados por herencia genética son los que se encuentran en la parte externa de los eritrocitos, varían en las diferentes poblaciones, por lo que son sujetos de importantes estudios diversas ramas de la medicina, en el área gineco-obstetricia, es importante identificar de forma temprana o preventiva una incompatibilidad sanguínea para favorecer la disminución de los índices de morbilidad y mortalidad neonatal, ya que puede derivar en una enfermedad hemolítica del recién nacido u otras complicaciones con mayor o menor grado. Objetivo: Recopilar la información más importante y actualizada sobre la incompatibilidad ABO. Metodología: Revisión sistemática documentos e investigaciones en inglés y español obtenidas de plataformas científicas como Elsevier, ScIELO, PubMed y de repositorios universitarios nacionales e internacionales desde el 2017, con descriptores como Sistema ABO, incompatibilidad sanguínea, materno-fetal, complicaciones, entre otras. Resultados: De un total de 112 documentos inicialmente, 62 fueron utilizados para la lectura de sus resúmenes, excluyéndose los demás por falta de relevancia con el tema de investigación o duplicación de la información. Conclusiones: La incompatibilidad sanguínea ABO es una complicación que genera reacción antígeno- anticuerpo y que puede llegar a ser mortal. Por ello, todas las ramas médicas; o por lo menos la gran mayoría, considera inicialmente realizar pruebas de tipificación sanguínea para aplicar los tratamientos correspondientes o determinar la causa etiológica de una patología asociada, sabiendo que existen procesos naturales en ginecología en los que la incompatibilidad ABO puede generar complicaciones importantes en el neonato como la enfermedad hemolítica del recién nacido, anemias o hiperbilirrubinemia grave, mismos que aumentan los índices de morbimortalidad.

show abstract

History and current standard of postnatal management in hemolytic disease of the fetus and newborn

et al. 2022

View full text Add to dashboard Cite

Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and neonatal red blood cells (RBC) are hemolyzed by maternal alloantibodies directed against RBC antigens potentially leading to severe disease. Preventative measures, such as Rhesus(D) immunoprophylaxis (RhIG), have greatly decreased the prevalence of Rh(D)-mediated HDFN, although a gap between high-income countries and middle-to low-income countries was created largely due to a lack in availability and high costs of RhIG. Other important developments in the past decades have improved the identification, monitoring, and care of pregnancies, fetuses, and neonates with HDFN. Prenatally, fetal anemia may occur and intrauterine transfusions may be needed. Postnatally, pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for anemia in the late phase of the disease. Through this review, we aim to provide an overview of important historic events and to provide hands-on guidelines for the delivery and postnatal management of neonates with HDFN. Secondarily, we aim to describe recent scientific findings and evidence gaps.Conclusion: Multiple developments have improved the identification, monitoring, and care of pregnancies and neonates with HDFN throughout the centuries. Pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for late anemia in the late phase of the disease. Future studies should be set in an international setting and ultimately aim to eradicate HDFN on a global scale. What is Known:• Developments have led to a greater understanding of the pathophysiology, an improved serological identification and monitoring of at-risk cases and the current pre-and postnatal treatment. What is New:• This review provides the pediatrician with hands-on guidelines for the delivery and postnatal management of neonates with HDFN.• Future studies should be set in an international setting with the ultimate aim of eradicating HDFN.

show abstract

Enfermedad hemolítica del feto y del recién nacido por aloanticuerpos contra el antígeno M

Cited by 6 publications

References 11 publications

Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease

Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease

Incompatibilidad ABO. Una revisión bibliográfica

History and current standard of postnatal management in hemolytic disease of the fetus and newborn

Contact Info

Product

Resources

About